The COVID-19 Assessment for Survival at Admission (CASA) Index: A 12 Months Observational Study

Gianluca Bagnato *, Daniela La Rosa 1, Carmelo Ioppolo, Alberta De Gaetano 1, Marianna Chiappalone, Natalia Zirilli 1, Valeria Viapiana 1, Maria Concetta Tringali 1, Simona Tomeo 1, Caterina Oriana Aragona 1, Francesca Napoli 1, Sara Lillo 2, Natasha Irrera 1, William Neal Roberts 3, Egidio Imbalzano 1, Antonio Micari 2, Elvira Ventura Spagnolo 4, Giovanni Squadrito 1, Sebastiano Gangemi 1 and Antonio Giovanni Versace 1

*Correspondence: Gianluca Bagnato gianbagnato@gmail.com

Specialty section: This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

Objective: Coronavirus disease 2019 (COVID-19) is a disease with a high rate of progression to critical illness. However, the stratification of patients at risk of mortality is not well defined. In this study, we aimed to define a mortality risk index to allocate patients to the appropriate intensity of care.

Methods: This is a 12 months observational longitudinal study designed to develop and validate a pragmatic mortality risk score to stratify COVID-19 patients aged ≥18 years and admitted to hospital between March 2020 and March 2021. Main outcome was in-hospital mortality.

Results: 244 patients were included in the study (mortality rate 29.9%). The Covid-19 Assessment for Survival at Admission (CASA) index included seven variables readily available at admission: respiratory rate, troponin, albumin, CKD-EPI, white blood cell count, D-dimer, Pa02/Fi02. The CASA index showed high discrimination for mortality with an AUC of 0.91 (sensitivity 98.6%; specificity 69%) and a better performance compared to SOFA (AUC = 0.76), age (AUC = 0.76) and 4C mortality (AUC = 0.82). The cut-off identified (11.994) for CASA index showed a negative predictive value of 99.16% and a positive predictive value of 57.58%.

Conclusions: A quick and readily available index has been identified to help clinicians stratify COVID-19 patients according to the appropriate intensity of care and minimize hospital admission to patients at high risk of mortality.

Keywords: COVID-19, outcome research, mortality risk, stratification index, systemic score

INTRODUCTION

Since the outbreak in Wuhan city, China on December 2019 of a viral pneumonia with an unidentified etiology (1), a novel strain of coronavirus was isolated and defined Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) by the Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses...
COVID-19 became the name of the disease that is induced by the aforementioned virus, which has caused a global pandemic accounting, as of May 8th 2021, for more than 3.2 million deaths worldwide as reported by WHO.

After more than one year from the original Chinese outbreak, national health systems are still facing devastating consequences due to the poor ability to control infection spreading and slow adaptation to the high number of hospital admissions. A lack of ability to easily stratify the patients on the first day of admission has further hampered efforts to influence the rate of mortality. Currently the overwhelming number of Sars-Cov-2 infected patients requiring hospitalization outpaces the availability of human and medical resources in several countries. All these conditions argue for the definition of a very high performing, predictive index of mortality to allow the appropriate allocation of COVID-19 resources (3). For maximum utility such an index would be constructed from elements of clinical and laboratory features available on the first day of hospitalization and applicable as a guide to reorganize dedicated COVID-19 divisions according to disease severity at admission and mortality risk (4). Paradoxically, identifying patients occupying the opposite end of the disease severity spectrum – those with very low or perhaps even no risk – can be equally useful to resource allocation. Clinicians and health care systems urgently warrant reliable scores to identify those patients with COVID-19 at highest risk for death requiring admission, to stratify them in the appropriate level of care and apply a rational optimization of resources. In addition, these instruments can also help clinician adopt quick and reliable clinical decisions and anticipate the prognosis to patients and their families.

Despite in the early phase of pandemic several other COVID-19 and non-COVID-19 specific scores have been employed in an attempt to stratify according to mortality or ICU admission risk, validation studies failed to confirm their applicability in larger populations (5–15). According to a recent review article analyzing the existing scores predicting COVID-19 mortality, the 4C mortality score, designed specifically for COVID-19, is likely to have the best performance, though it has intrinsic limitations and a relatively low positive predictive value (16–18).

Our aim was, then, to identify a COVID-19 specific score to predict mortality with improved positive predictive value and comparable very high negative predictive value, thus reducing the number of COVID-19 patients requiring medium-high intensity of care and concentrating patients at risk of mortality in adequately skilled and equipped divisions. Early stratification of patients who are either highly prone to develop critical disease, or are substantially protected from it, is of undoubted importance in guiding the clinician in delivering proper care and optimizing use of limited health resources.

Thus, we aimed to build a mortality risk prediction score for an ascertainment set of consecutive patients with COVID-19 and radiologic evidence of pneumonia based entirely upon data available on the day of admission.

**MATERIALS AND METHODS**

This is a single center, longitudinal, observational study involving consecutive admitted patients aged ≥18 years and diagnosed with Sars-Cov-2 infection and radiologic evidence of pulmonary involvement. The study enrollment period was 1 year time from March 2020 to March 2021 in the critical medicine division of the University of Messina. Patients directly admitted in ICU were not included in our study. In addition, we excluded patients who were either admitted with non-COVID-19 symptoms and had incidental asymptomatic diagnosis (e.g. hip fracture without clinical features of COVID-19), those admitted for isolation/control reasons, and also those with COVID-19 who were discharged from either ambulatory care or the emergency room, without admission. Among 249 eligible patients, 5 were excluded due to missing data at admission. A total of 244 patients with confirmed Sars-Cov-2 infection and radiologic evidence of pulmonary involvement were thus enrolled in the study. Oropharyngeal and nasal swab samples were taken from all patients upon hospital admission. Patients with a positive result of swabs, confirmed by real time reverse transcriptase polymerase chain reaction, and radiologic evidence of pneumonia were included in the study. The study was approved by the institutional review board of the University of Messina and informed consent was obtained from all subjects. They all agreed to routine access to their record and analysis of their medical history data at the time of admission.

**Data Collection**

The demographic (age, sex, home isolation, in-hospital stay, smoking exposure, body mass index and comorbidity), clinical (vital parameters and signs/symptoms), laboratory parameters at admission,Ordinal Scale for Clinical Improvement (19), therapeutic regimen and the final outcomes (the deceased/survivors, ICU transfer) of the enrolled patients were prospectively collected. The following new onset signs/symptoms were included: fever, cough, shortness of breath, confusional state and Coma Glasgow Scale, diarrhea, fatigue, headache, nausea or vomiting, sore throat, sputum production, arthralgia or myalgia. Comorbidities collected were: chronic cardiac disease, chronic respiratory disease, chronic renal disease, dementia, chronic neurological conditions, connective tissue disease, thyroid disease, diabetes mellitus and malignancy.

The laboratory parameters included were: hemoglobin, platelet count, red cell count, white cell count, lymphocyte count, hematocrit (HCT), C-reactive protein (CRP), procalcitonin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), albumin, ferritin, fibrinogen, urea, creatinine, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (CKD-epi) for the assessment of Estimated glomerular filtration rate troponin, NT-Pro-BNP and D-dimer, PaO2/FiO2 ratio. The clinical information used to calculate prognostic scores was taken from the day of hospital admission.
Outcomes
The primary outcome of the study was in-hospital mortality. This outcome was selected because of its face validity. We considered of primary interest the stratification of patients according to the mortality risk in order to be able to escalate intensity of care and therapeutic regimen for patients likely to develop severe illness from SARS-CoV-2 infection.

Independent Predictor Variables
A reduced set of potential predictor variables was selected a priori, including patient demographic information, common clinical investigations, and parameters consistently identified as clinically important in COVID-19 cohorts, as previously reported (20).

Candidate predictor variables were selected based on two common criteria: variables known to influence outcome in pneumonia and flulike illness; clinical biomarkers previously identified within the literature as potential predictors in patients with COVID-19 (21–23).

Statistical Analysis and Model Development
Continuous and categorical variables were presented as median (IQR) and n (%), respectively. We used the Mann-Whitney U test or Fisher’s exact test to compare differences between survivors and non-survivors where appropriate.

The primary intention was to create a pragmatic model for use during admission to stratify patients for intensity of care, maximizing for sensitivity and specificity in order to exclude those not requiring a medium-high intensity of care. We used the following steps to build the model: firstly, univariable logistic regression analysis was performed for all the variables that were significant in the between-group analysis. Since age was independently associated with the outcome of interest (the deceased vs. survivors), we performed age-adjusted univariable logistic regression for the variables significant in the first round of univariable logistic regression analysis after categorizing them according to laboratory reference range or clinical criteria where appropriate.

To enhance a pragmatic approach, the significant age-adjusted variables were plotted in their categorized form, according to the reference range of the test (present/absent), in multivariable logistic regression analysis with backward stepwise method.

The model retained 7 variables, thus minimizing the risk of overfitting according to the number of events occurred ($n = 73$). A score was then created by multiplying the odds ratio of each relevant variable. Receiver operating characteristics (ROC) curves were used to assess the accuracy of model predictions and area under curve (AUC) with negative predictive value (NPV), positive predictive value (PPV), specificity and sensitivity was given and compared to the results of age, SOFA and 4C mortality scores according to De Long et al. (24).

RESULTS
Demographics characteristics, vital parameters, clinical features and comorbidities at admission for the entire study population and for the group of deceased patients (73) and survivors ($n = 171$) are collected in Table 1, while Table 2 shows the laboratory results. The mortality rate of our study population was 29.9%, while 13.5% were transferred in ICU. Patients were treated with the following medications: 87% with corticosteroids, 85% with heparin, 16% with hydroxychloroquine. No patients were treated with remdesivir, tocilizumab, plasma hyperimmune or monoclonal antibodies.

Comparison of Demographics and Clinical Characteristics Between Survivors and Deceased Patients at Admission
As initial analysis, we sought to compare the profile of patients according to the outcome of interest. Among the demographic features, deceased patients were older, while no differences were observed in gender prevalence or BMI between the groups. Next, we analyzed the differences in the prevalence of comorbidities between survivors and deceased. History of chronic kidney disease, coronary artery disease and heart failure were more frequent in deceased patients, while no differences were found for hypertension or diabetes prevalence. Neurologic features were also significantly different between survivors and deceased: both dementia and cerebrovascular disease prevalence were significantly higher in the deceased groups and, accordingly, new onset confusional state and lower Glasgow Coma Scale were more frequently identified in the group of deceased patients. In addition, while a positive history of COPD or respiratory failure was not more frequent in deceased patients, both a higher respiratory rate and the presence of shortness of breath at admission were common features in deceased patients compared to survivors. On the contrary, the presence of arthralgia or myalgia is a common finding in subjects who survive.

Comparison of Laboratory Results Between Survivors and Deceased Patients at Admission
Initially, we evaluated the laboratory results at admission of the groups to identify the relevant discriminants of deceased patients. The subjects belonging to each group were then categorized according to the cut-off laboratory reference. In accordance with the comorbidities profile, a higher prevalence of chronic kidney disease, heart failure and coronary artery disease in deceased patients corresponded to a higher troponin T and NT-PRO-BNP levels and also higher urea and creatinine levels with concomitant lower CKD-EPI compared to survivors. In addition, both low platelet count and high white blood cell count and procalcitonin levels were more common in deceased patients compared to survivors with no difference in lymphocytes levels. On the contrary, low white blood cells count was more common in survivors compared to deceased patients. Among the inflammatory markers both CRP and fibrinogen were significantly higher in the deceased group, while no between-group difference was found in ferritin levels. Furthermore, albumin, D-Dimer, LDH and AST levels were significantly higher in deceased patients, while ALT and total bilirubin levels were not different between deceased and survivors.
|                     | Total  | Deceased | Survivors | p     |
|---------------------|--------|----------|-----------|-------|
| **Demographics**    |        |          |           |       |
| Age, median (IQR)   | 72.3 (24.8) | 79.7 (12.7) | 69 (23.0) | < 0.001 |
| Over 65 years, n (%)| 155 (67.6) | 66 (90.4) | 99 (57.9) | < 0.001 |
| BMI, median (IQR)   | 25.4 (4.6) | 25.7 (5.2) | 25.2 (4.7) | 0.228 |
| Home isolation, days| 1 (3.8) | 0 (2.5) | 1 (4) | 0.518 |
| Smoking, current    | 35 (14.3) | 9 (12.3) | 26 (15.2) | 0.356 |
| Smoking, past       | 29 (11.9) | 14 (19.1) | 15 (8.7) | 0.07 |
| Gender, male        | 135 (55.3) | 38 (52) | 97 (56.7) | 0.297 |
| **Comorbidities**   |        |          |           |       |
| Dementia            | 70 (28.6) | 30 (41) | 36 (21) | < 0.001 |
| Diabetes            | 70 (28.6) | 24 (32.8) | 46 (26.9) | 0.214 |
| Asthma              | 3 (1.2) | 3 (1.7) | 0 (0) | 0.342 |
| Autoimmune diseases | 4 (2) | 1 (1.3) | 4 (2.3) | 0.529 |
| Coronary artery disease | 51 (20.9) | 21 (28.7) | 30 (17.5) | 0.038 |
| Myocardial infarction| 10 (4) | 4 (5.4) | 6 (3.5) | 0.346 |
| COPD                | 28 (11.4) | 8 (10.9) | 20 (11.7) | 0.531 |
| Heart failure       | 44 (18) | 20 (27.4) | 24 (14) | 0.012 |
| Hypertension        | 155 (63.5) | 46 (63) | 109 (63.7) | 0.513 |
| Malignancy          | 23 (9.4) | 10 (13.7) | 13 (7.6) | 0.107 |
| Chronic kidney disease | 74 (30.3) | 40 (54.8) | 34 (19.8) | < 0.001 |
| Stroke              | 11 (4.5) | 6 (8.2) | 5 (2.9) | 0.0801 |
| Cerebrovascular disease | 43 (17.6) | 19 (26) | 24 (14) | 0.021 |
| Thyroid disease     | 12 (4.9) | 6 (8.2) | 6 (3.5) | 0.271 |
| Respiratory failure | 12 (4.9) | 4 (5.4) | 8 (4.6) | 0.507 |
| **Clinical presentation** | |       |           |       |
| Confusional state   | 58 (23.7) | 24 (32.8) | 34 (19.8) | 0.023 |
| Cough               | 101 (41.4) | 28 (38.3) | 73 (42.7) | 0.314 |
| Diarrhea            | 20 (8.2) | 5 (6.8) | 15 (8.7) | 0.414 |
| Fatigue             | 126 (51.6) | 32 (43.8) | 94 (54.9) | 0.073 |
| Fever               | 99 (40.5) | 30 (41) | 69 (40.3) | 0.512 |
| Headache            | 45 (18.4) | 9 (12.3) | 36 (21) | 0.074 |
| Nausea or vomiting  | 27 (11) | 9 (12.3) | 18 (10.5) | 0.506 |
| Shortness of breath | 132 (54) | 55 (75.3) | 77 (45) | < 0.001 |
| Sore throat         | 59 (24.1) | 19 (26) | 40 (23.4) | 0.451 |
| Sputum production   | 25 (10.2) | 9 (12.3) | 16 (9.3) | 0.120 |
| Arthralgia or myalgia | 65 (26.6) | 9 (12.3) | 56 (32.7) | 0.001 |
| OSCI                | 5.1 (0.8) | 5.3 (1.3) | 4.9 (0.9) | 0.437 |
| **Vital parameters** |        |          |           |       |
| Heart rate          | 80 (17.5) | 80 (23) | 80 (14) | 0.068 |
| DBP, mmHg           | 70 (20) | 70 (20) | 70 (16) | 0.355 |
| SBP, mmHg           | 130 (35) | 125 (40) | 130 (35) | 0.541 |
| MBP, mmHg           | 90 (21.5) | 88 (25) | 91 (21) | 0.402 |
| Respiratory Rate    | 18 (6) | 24 (7) | 18 (4) | < 0.001 |
| Respiratory Rate >20| 82 (33.6) | 50 (68.5) | 32 (18.7) | < 0.001 |
| CGS                 | 15 (2) | 13 (4) | 15 (8) | < 0.001 |

CGS, Coma Glasgow Scale; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; MBP, Medium Blood Pressure; BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; OSCI, Ordinal Scale for Clinical Improvement.
| Laboratory results | Total (n = 244) | Deceased (n = 73) | Survivors (n = 171) | p |
|-------------------|----------------|------------------|---------------------|---|
| Albunim, g/dL     | 3.07 (0.8)     | 2.7 (0.6)        | 3.21 (0.6)          | < 0.001 |
| Albunim ≤ 2.5     | 18 (7.7)       | 15 (21.4)        | 3 (1.8)             | < 0.001 |
| ALT, UI/L         | 21 (20.5)      | 23 (24)          | 20 (17)             | 0.084  |
| AST, UI/L         | 26 (20.8)      | 33 (29)          | 24 (15)             | < 0.001 |
| AST ≥ 42          | 52 (21.3)      | 26 (35.6)        | 26 (15.2)           | 0.001  |
| CKD-EPI, ml/min   | 71.9 (50.1)    | 43.5 (64.5)      | 79.1 (36.5)         | < 0.001 |
| CKD-EPI ≤ 60      | 94 (38.5)      | 48 (65.7)        | 46 (26.9)           | < 0.001 |
| OK, U/L           | 90 (301)       | 100 (184)        | 0.177               |
| Creatinin, mg/dL  | 1 (0.7)        | 1.3 (1.4)        | 0.9 (0.5)           | < 0.001 |
| Creatinin ≥ 1.2   | 77 (31.5)      | 38 (22)          | 39 (53.4)           | < 0.001 |
| D-Dimer, mcg/mL   | 1 (1.5)        | 1.86 (3.2)       | 0.84 (1)            | < 0.001 |
| D-Dimer ≥ 4       | 33 (13.6)      | 24 (33)          | 9 (5.2)             | < 0.001 |
| LDH, U/L          | 444.5 (324)    | 678.5 (596.5)    | 403 (196.3)         | < 0.001 |
| LDH ≥ 450         | 114 (46.7)     | 53 (72.6)        | 61 (35.7)           | 0.081  |
| NT-PRO-BNP, pg/mL | 433.5 (2082.5) | 2748.5 (7901)    | 229.5 (690.3)       | < 0.001 |
| NT-PRO-BNP > 125  | 149 (61)       | 64 (87.6)        | 112 (65.4)          | < 0.001 |
| Ferritin, mg/mL   | 621 (678)      | 786 (773)        | 487 (676)           | 0.046  |
| Ferritin ≥ 300    | 180 (73)       | 69 (64.5)        | 117 (68)            | 0.018  |
| Fibrinogen, mg/dL | 527 (253)      | 562 (274)        | 515 (218)           | 0.017  |
| Fibrinogen ≥ 400  | 192 (78.6)     | 61 (83.5)        | 131 (76.3)          | 0.173  |
| Hb, gr/dL         | 12.9 (2.8)     | 12.2 (3.5)       | 13 (2.4)            | 0.295  |
| PaO2/FiO2 ratio   | 295.2 (160.9)  | 209.2 (213.4)    | 319 (126)           | < 0.001 |
| PaO2/FiO2 ≤ 300   | 128 (52.4)     | 54 (73.9)        | 74 (43.2)           | < 0.001 |
| CRP, mg/dL        | 4.19 (10.2)    | 10.76 (14)       | 2.69 (6.2)          | < 0.001 |
| CRP ≥ 0.5         | 198 (81.1)     | 67 (91.7)        | 131 (76.6)          | < 0.001 |
| PCT, ng/mL        | 0.11 (0.22)    | 0.31 (1.13)      | 0.8 (0.11)          | 0.002  |
| PCT ≥ 0.5         | 44 (18)        | 30 (41)          | 14 (8)              | < 0.001 |
| PLT, cells x 10^4 | 20.9 (11.6)    | 16.6 (16.2)      | 21.3 (10.8)         | < 0.001 |
| PLT ≤ 15 x 10^4   | 51 (20.9)      | 21 (28.7)        | 30 (17.5)           | 0.038  |
| Total bilirubin, mg/dL | 0.52 (0.5) | 0.69 (0.7) | 0.51 (0.4) | 0.131 |
| Troponin, pg/mL   | 26.5 (48)      | 60 (129.5)       | 18 (23.9)           | < 0.001 |
| Troponin ≥ 14     | 170 (69.6)     | 66 (90.4)        | 104 (60.8)          | < 0.001 |
| Urea, mg/dL       | 49 (48)        | 79.5 (75.5)      | 40 (28)             | < 0.001 |
| Urea ≥ 50         | 115 (47.3)     | 55 (75.3)        | 60 (35)             | < 0.001 |
| WBC, cells x 10^9 | 7.5 (6.1)      | 10.5 (7)         | 6.7 (4.2)           | < 0.001 |
| WBC ≤ 4x10^9      | 29 (11.9)      | 4 (5.4)          | 25 (16.8)           | 0.030  |
| WBC ≥ 10x10^9     | 78 (32)        | 40 (64.8)        | 38 (22.2)           | < 0.001 |
| Lymphocyte count  | 1269.5 (880.8) | 1,176 (794)      | 1,300 (883)         | 0.386  |

Data are expressed as median (interquartile range) or number (percentages) accordingly. WBC, white blood cells; PLT, platelet cells; PCT, procalcitonin; Hb, haemoglobin; CRP, C-reactive protein; NT-PRO-BNP, N-terminal pro-brain natriuretic peptide; LDH, lactate dehydrogenase; CK, creatine kinase; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; AST, aspartate transaminase; ALT, Alanine transaminase.

**Age-Adjusted Univariable Logistic Regression Analysis and Multivariable Model Definition**

After identifying the factors that were statistically significant in the deceased group, univariable logistic regression analysis was performed after adjusting for age, as it resulted to be the unique significantly different variable among the demographic characteristics of our study population (Table 3). After adjusting for age, only history of chronic kidney disease remained significant among comorbidities, while age correction did not affect the significance of the factors belonging to clinical presentation and vital parameters. Laboratory results remained all significant apart from NT-PRO-BNP. After ruling out variables from the multivariable analysis according to the differences between-group (Tables 1, 2), we further excluded...
those variables from the multivariable analysis if they had multicollinearity (urea, creatinine and history of CKD, shortness of breath). Next, we compared the difference between deceased and survivors according to the variables significant in age-adjusted univariable logistic regression by classifying them in binary format according to the laboratory reference range.

### DISCUSSION

After more than 1 year from the onset of the pandemic and the appearance of SARS-COV-2 variants, despite the attempts to start intense vaccination programs, the management of COVID-19 mortality still remains imperfect.

In the balance between rate of admission, mortality risk and disease progression toward severe acute respiratory and multi-organ failure it appears crucial to identify and stratify patients. If highly accurate, such stratification will help to compensate for the uncontrolled virus contagiousness and to prepare highly equipped division for patients needing multi-organ support.

Herein, aiming at stratifying patients for mortality risk at admission, we have developed the seven variables CASA index score in an Italian prospective cohort study involving 244 patients consecutively admitted to the hospital with COVID-19 over 12 months. The CASA index employs only clinical and blood parameters that are commonly available at the time of hospital admission to predict mortality. In addition, the definition of the relevant parameters that increase the risk of mortality has been supported by age-adjustment in our study. While it is widely...
accepted that older age increases the risk of mortality (25, 26), age alone is not sufficient to stratify patients for intensity of care, while, on the other hand, age remains the main demographic characteristic to consider when building a score for COVID-19. The identification of patients at risk of mortality is particularly challenging due to the onset of systemic complications of COVID-19 and the evolution toward acute respiratory distress syndrome (ARDS). Traditionally, ARDS presents non-specific manifestations though it should be suspected in those presenting progressive symptoms of respiratory distress, an increasing requirement for oxygen, and alveolar infiltrates on chest imaging. However, several reports suggest that COVID-19 related ARDS is atypical (27–29), mostly due to the discrepancies between blood gas, peripheral saturation (SpO2), lung compliance and the occurrence of systemic complications. Indeed, SpO2 alone might be misleading in assessing COVID-19 pneumonia evolution due to the evidence that these patients present depressed PaO2 values with satisfactory SpO2. This has been defined as “happy” or silent hypoxia, which might lead to an underestimation of the disease severity and influence the clinical decision of the appropriate admission allocation and/or delay intensive treatment (30). Silent hypoxemia is better identified by a significantly increased respiratory rate, which in contrast to hypercapnia that generates dyspnea, seems to not induce dyspnea. This could be due to a possible damage to the afferent hypoxia-sensing neurons, induced by the intense cytokine storm or the direct effect of SARS-CoV-2 (31–34). Compared to lower commonly employed PaO2/FiO2 value ≤200 or less, in an attempt to identify more patients in an early phase of disease progression, we included in our index a PaO2/FiO2 value ≤300, as supported by the “Berlin definition” of acute respiratory distress (34, 35). Signs of respiratory distress, such as tachypnea, and worsening PaO2/FiO2 were included in our index as they revealed to be independent predictors of mortality. Hence, these factors should be closely monitored, as a sudden and rapidly evolving disease can involve patients in stable conditions (36).

Apart from the lung-specific alterations, several other systemic complications have been reported in severe cases of COVID-19. The interactions between the cardiovascular system, the pulmonary system and kidney function in fatal cases of COVID-19 are complex and multifaceted and also influenced by the activation of the immune system and the coagulation cascade (37). Preexisting coronary artery disease has been frequently observed in fatal cases of COVID-19 and increased troponin levels have been identified as an independent predictor of mortality (38). In COVID-19 the mechanism of troponin elevation is not fully understood, since it might be related to both ischemic injury, less frequently, and non-ischemic damage, such as pneumonia, sepsis, myocarditis, systemic inflammation, pulmonary thrombosis and cardiac adrenergic hyperstimulation during cytokine storm (39). Several reports confirm that all causes of troponin levels elevation are related with the severity of COVID-19 infection and, of note, with disease progression to major complications like multi-organ failure and death (40). In line with previous studies, our results show that normal cardiac troponin levels at admission have a very high negative predictive value for all causes of in-hospital mortality and are a very strong
and independent indicators of hospital survival in COVID-19 patients (41). On the other hand, we hypothesize that a high level on admission may help us identify and stratify the subgroup of patients who may progress toward severe complications and death.

To further confirm the complexity of the systemic alterations involving the cardiocirculatory system, several reports suggest that a depressed kidney function at admission, identified by a glomerular filtration rate <60 ml/min, represents an independent predictor of mortality (42), and this also is evidenced by our results. The hematological profile in COVID-19 has been regularly associated with a hypercoagulable status with elevated D-dimer, which in turn might worsen vital organ function (43), and contributes to the development of complications such as ARDS, ICU access, and death (44). The correct identification of COVID-19 subgroups prone to develop either systemic thromboembolism, often associated with a strong immunoinflammatory response (45), or localized forms of coagulopathy, such as the "pulmonary intravascular coagulopathy" (46), remains difficult. Still, the uncontrolled activation of the coagulation system is one of the unique mainstays of COVID-19, leading to increased mortality (29).

In addition, another hematological aspect has emerged in our analysis. While lymphopenia has been invariably linked to the disease itself irrespective of the severity status, leucocytosis is common in patients with aggressive evolution (47), thus adding the disruption of the immune system associated with possible bacterial infection as an additional mortality risk factor, and supporting the relevance of a dynamic monitoring for the early identification of white blood cell increase (48).

Finally, several reports suggest that albumin levels are inversely correlated with the white blood cell count, suggesting that the dysregulated immune response causes an augmented capillary permeability and an extravasation of serum albumin into the interstitial space. Infact, hypoalbuminemia has been already reported as a marker of disease severity and increased hospital mortality in past SARS epidemics (49). It is known that reduced serum albumin levels are found in patients with COVID-19 (50, 51) and in general albumin levels below 2/2.5 g/L are associated with ARDS severity (52). According to other studies on COVID-19 patients, it has been suggested that even a higher serum albumin level cut-off, such as 3.5 g/L at presentation independently increases the risk of death in COVID-19 (49, 53, 54).

Our study has some limitations: firstly, we were unable to evaluate the predictive performance of several existing scores that require a larger number of parameters (for example, APACHE II, PSI), as well as other COVID-19 prognostic scores that use computed tomography findings or uncommonly measured biomarkers. However, we were able to compare the performance of CASA index to the COVID-19 specific 4C mortality index, in addition to age and SOFA. Thus, by including comparisons with pre-existing models, reassurance is provided that equivalent performance cannot be delivered with a simple tool already in use, or at least not one that can be applied on the first hospital day. In addition, treatment regimen, limited by the availability of specific emerging therapy, might have influenced the primary outcome. The sample size involved in the study, while covering a long-term observation, requires validation studies in other cohorts to confirm our findings. Nevertheless, the size of our patient cohort compares favorably to other datasets for model creation. The patient cohort on which the 4C Mortality Score was derived also comprised patients admitted to hospital who were seriously ill (mortality rate of 32.2%) and were of advanced age (median age 72.3 years). Thus, the CASA index is not for use in the community and will likely perform differently in populations at lower risk of death. Further external validation is required to determine whether our index is applicable in other populations.

In conclusion, there is an increased need for tools to stratify patients for intensity of care and to specifically exclude from medium-high intensity divisions those patients not at risk of death. The complex systemic disturbances occurring during COVID-19 remain difficult to ascertain, as does the practical distinction between subjects with a self-limiting disease and those evolving toward acute respiratory syndrome and multi-organ failure. Our index may prove useful to stratify those who are candidates for admission to medium-high intensity of care units and to improve the allocation of equipment and human resources to prepare health system to adapt according to the unpredictable evolution of COVID-19. In addition, the CASA index, due to its easy applicability in emergency departments, facilitates the stratification of medium-low intensity patients to the appropriate division by including a systemic view of the disease, including extrapulmonary manifestations. Covering a wide range of COVID-19 patients requiring non-ICU hospitalization, as expressed by the Ordinal Scale for Clinical Improvement, the CASA index might prove useful in stratifying patients to the appropriate intensity of care and have a large-scale use due to its quick feasibility at admission. Further validation studies are needed to confirm the performance of the index and to test the limits of its generalizability.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by University of Messina. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

GB, DLR, CI, MC, AD, MT, NZ, ST, NI, AV, WR, SG, and GS concept and design of the study. CA, FN, VV, GB, CI, MC, NI, and ST data collection, data analysis and interpretation. SG, EV, GS, WR, GB, EI, and AM manuscript preparation. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.719976/full#supplementary-material
REFERENCES

1. Ji W, Wang W, Zhao X, Zai J, Li X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. (2020) 92:433–40. doi: 10.1002/jmv.25862

2. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. (2020) 5:536–44. doi: 10.1038/s41556-020-0695-z

3. De Larochelambert Q, Marc A, Antero J, Le Bourg E, Toussaint JP. Covid-19 mortality: a matter of vulnerability among nations facing limited margins of adaptation. Front Public Health. (2020) 8:604339. doi: 10.3389/fpubh.2020.604339

4. Sesta L, Mondello C, Cardia L, Mondello E, Baldino G, Spagnolo EV. Covid-19 in Italy. Clinical emergency and bioethical perspectives. EuroMediterranean Biomed J. (2020) 15:121–25. doi: 10.3269/1970-5492.2020.15.30

5. Bradley P, Frost E, Tharmaratnam K, Wootton DG. Research NWCOfR. A novel severity score to predict inpatient mortality in COVID-19 patients. J Clin Med. (2020) 9:3066. doi: 10.3390/jcm903066

6. Lopez-Escobar A, Preetam M. Validation of PSI/PORT, CURB-65 and SCAP scoring systems in COVID-19 pneumonia for prediction of disease severity and 14-day mortality. Clin Respir J. (2021) 21:198. doi: 10.1186/s12931-020-01462-5

7. Del Villar R, Menendez J, et al. Risk score for predicting in-hospital mortality in COVID-19 (RIM Score). Med (N Y) 2021 21:571–76. doi: 10.1001/jamainternmed.2020.12013

8. Basir A, Talbi H, Rousle M, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. (2020) 8:1201–08. doi: 10.1016/S2213-2600(20)30370-2

9. Potgieter JS, Wessels S, et al. COVID-19 pneumonia: different respiratory mechanisms in COVID-19. Respir Med. (2020) 162:105710. doi: 10.1016/j.rmed.2020.10.016

10. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel severity score to predict inpatient mortality in COVID-19 patients. Sci Rep. (2020) 10:16726. doi: 10.1038/s41598-020-73962-9

11. Guan WJ Ni ZY, Hu Y, Liang WH, et al. Clinical characteristics of 991 patients in Wuhan with COVID-19 pneumonia requiring mechanical ventilation. N Engl J Med. (2020) 382:1708–20. doi: 10.1056/NEJMoa2002032

12. Rapp JL, Lieberman-Cribbin W, Tuminello S, Taioli E. Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York City. Chest. (2021) 159:112–15. doi: 10.1016/j.chest.2020.08.2065

13. Gencer S, Lacy M, Atzler D, van der Vorst EPC, Doring FM, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. (2020) 46:1099–102. doi: 10.1007/s00134-020-06033-2

14. Swenson KE, Ruoss SJ, Swenson ER. The pathophysiology and dangers of silent hypoxemia in COVID-19 lung injury. Ann Am Thorac Soc. (2021) 18:1908–105. doi: 10.1513/AnnalsATS.202011-1376CM

15. González-Duarte A, Norcliffe-Kaufmann L, Bellani G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. (2020) 8:1201–08. doi: 10.1016/S2213-2600(20)30370-2

16. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. (2012) 307:2526–33. doi: 10.1001/jama.2012.5669

17. Friedman HJ, Hines DW. Performance of the quick COVID-19 severity index in COVID-19 pneumonia requiring mechanical ventilation. Clin Infect Dis. (2020) 71:833–40. doi: 10.1093/cid/ciaa443

18. Vela M, et al. The PANDEMYC Score. An easily applicable and interpretable model for predicting mortality associated with COVID-19. J Clin Med. (2020) 9:3066. doi: 10.3390/jcm903066

19. Elgart JB, Shaffer S, et al. COVID-19: a prospective observational multicentre study. BMJ Open. (2020) 10:e03651. doi: 10.1136/bmjopen-2020-03651

20. Sampaio M, Arakaki C, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C Mortality Score. BMJ. (2020) 370:m3339. doi: 10.1136/bmj.m3339

21. Gonzalez-Duarte A, Norcliffe-Kaufmann L, Bellani G, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet Respir Med. (2020) 8:1201–08. doi: 10.1016/S2213-2600(20)30370-2
38. Gaze DC. Clinical utility of cardiac troponin measurement in COVID-19 infection. *Ann Clin Biochem.* (2020) 57:202–05. doi: 10.1177/0004563220921888

39. Imazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, et al. COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? *Heart.* (2020) 106:1127–31. doi: 10.1136/heartjnl-2020-317186

40. Metkus TS, Guallar E, Sokoll L, Morrow D, Tomaselli G, Brower R, et al. Prevalence and prognostic association of circulating troponin in the acute respiratory distress syndrome. *Crit Care Med.* (2017) 45:1709–17. doi: 10.1097/CCM.0000000000002641

41. Al Abbasi B, Torres P, Ramos-Tuarez F, Dewaswala N, Abdallah A, Chen K, et al. Cardiac troponin-I and COVID-19: a prognostic tool for in-hospital mortality. *Cardiol Res.* (2020) 11:398–404. doi: 10.14740/ cr1159

42. Trabulus S, Karaca C, Balkan, II, Dincer MT, Murt A, Ozcan SG, et al. Kidney function on admission predicts in-hospital mortality in COVID-19. *PloS ONE.* (2020) 15:e0238680. doi: 10.1371/journal.pone.0238680

43. Salabei JK, Fishman TJ, Asnake ZT, Ali A, Iyer UG. COVID-19 coagulopathy: current knowledge and guidelines on anticoagulation. *Heart Lung.* (2021) 50:357–60. doi: 10.1016/j.hrtlng.2021.01.011

44. Arachchilage DRJ, Lablan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* (2020) 18:1233–34. doi: 10.1111/jth.14820

45. Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. Immuneopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications. *Int J Mol Sci.* (2020) 21:4782. doi: 10.3390/ijms21134782

46. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. *Int J Hematol.* (2021) 113:45–57. doi: 10.1007/s12185-020-03029-y

47. Mehta AA, Haridas N, Belgundi P, Jose WM. A systematic review of clinical and laboratory parameters associated with increased severity among COVID-19 patients. *Diabetes Metab Syndr.* (2021) 15:535–41. doi: 10.1016/j.dsx.2021.02.020

48. Zhong Z, Li H, Zhu J, Ji P, Li B, Pang J, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis.* (2020) 71:762–68. doi: 10.1093/cid/ciaa248

49. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Hypoalbuminemia: pathogenesis and clinical significance. *JPEN J Parenter Enteral Nutr.* (2019) 43:181–93. doi: 10.1002/jpen.1451

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.